Hypertensive therapy: attacking the renin-angiotensin system.
作者信息
Bishop T, Figueredo V M
机构信息
Department of Internal Medicine (Cardiology), University of New Mexico Health Sciences Center, 5400 Gibson Blvd SE, Albuquerque, NM 87108, USA.
出版信息
West J Med. 2001 Aug;175(2):119-24. doi: 10.1136/ewjm.175.2.119.
Abstract
摘要
相似文献
1
Hypertensive therapy: attacking the renin-angiotensin system.
West J Med. 2001 Aug;175(2):119-24. doi: 10.1136/ewjm.175.2.119.
2
From viper's venom to drug design: treating hypertension.
FASEB J. 2004 Mar;18(3):421. doi: 10.1096/fj.03-1398bkt.
3
The evolution of renin-angiotensin blockade: angiotensin-converting enzyme inhibitors as the starting point.
Curr Hypertens Rep. 2010 Apr;12(2):67-73. doi: 10.1007/s11906-010-0091-9.
4
A vaccine for hypertension.
J Hypertens. 2007 Jan;25(1):41-6. doi: 10.1097/HJH.0b013e328012981b.
5
Concept of anti-renin system therapy. Historic perspective.
Am J Med. 1984 Aug 20;77(2A):1-6. doi: 10.1016/s0002-9343(84)80051-0.
6
FDR and hypertension: if we'd only known then what we know now.
Geriatrics. 1996 Jan;51(1):29-32.
7
Renoprotective effects of renin-angiotensin-aldosterone system blockers in type 2 diabetes: demystifying multiple treatment comparisons in a network meta-analysis.
Diabetologia. 2012 Sep;55(9):2547-8; author reply 2549-50. doi: 10.1007/s00125-012-2619-9. Epub 2012 Jun 23.
8
A new class of antihypertensive therapy: angiotensin II receptor antagonists.
Pharmacotherapy. 1996 Sep-Oct;16(5):849-60.
9
The discovery of captopril: a reply.
FASEB J. 2004 Jun;18(9):935. doi: 10.1096/fj.04-1992lte.
10
[Blockers of renin-angiotensin-aldosterone system in the treatment of arterial hypertension: classics versus the modern].
Kardiologiia. 2013;53(10):89-95.
本文引用的文献
1
Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan.
Am J Cardiol. 2001 Mar 15;87(6):766-71, A7. doi: 10.1016/s0002-9149(00)01500-9.
2
Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.
Am Heart J. 2000 Nov;140(5):727-50. doi: 10.1067/mhj.2000.108832.
3
Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism.
Br J Pharmacol. 2000 Sep;131(1):138-44. doi: 10.1038/sj.bjp.0703544.
4
Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy.
Kidney Int. 2000 Aug;58(2):762-9. doi: 10.1046/j.1523-1755.2000.00224.x.
5
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.
Lancet. 2000 May 6;355(9215):1582-7. doi: 10.1016/s0140-6736(00)02213-3.
6
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.
Lancet. 2000 May 6;355(9215):1575-81. doi: 10.1016/s0140-6736(00)02212-1.
7
Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists.
Kidney Int. 2000 May;57(5):1803-17. doi: 10.1046/j.1523-1755.2000.00031.x.
8
The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
Nephrol Dial Transplant. 2000 Apr;15(4):487-97. doi: 10.1093/ndt/15.4.487.
9
10
Role of kinins in chronic heart failure and in the therapeutic effect of ACE inhibitors in kininogen-deficient rats.
Am J Physiol Heart Circ Physiol. 2000 Feb;278(2):H507-14. doi: 10.1152/ajpheart.2000.278.2.H507.
Zotero 插件